Sponsors

Lead Sponsor

InSightec

Age

50 - No limit years

Sex

MALE

Healthy Volunteers

No

Inclusion Criteria

•Biopsy proven adenocarcinoma of the prostate
•Intermediate risk, organ-confined prostate cancer (T1a up to T2b) and voluntarily chooses Exablate, who may currently be on watchful waiting or active surveillance and not in need of imminent radical therapy
•Up to 2 MRI visible Gleason 7 confirmed on mapping prostate biopsy that Investigator deems treatable within a single treatment session; may have secondary Gleason 6 on ipsilateral or contralateral side confirmed with biopsy and/or MRI
•PSA less than or equal to 20ng/mL

Exclusion Criteria

•Evidence of distant prostate cancer including lymph node involvement and/or metastasis of cancer
•Subject undergoing androgen deprivation therapy, initiating any new medication that can affect PSA, or history of bilateral orchiectomy
•Active bladder cancer, active UTI, or untreated prostatitis
•Untreated urethral stricture/bladder neck contracture
•Prostate-specific chemotherapy, brachytherapy, cryotherapy, photodynamic therapy, radical prostatectomy, or focal therapy (excluding FUS); or any prior radiation therapy to the pelvis for prostate cancer or any other malignancy
•Subjects with pathology or implants that may adversely impact treatment due to acoustics, imaging, or safe probe insertion
•Subject not able or willing to tolerate the required prolonged stationary supine position during treatment
•Contraindications to MRI

Related studies

RECRUITINGPhase 3

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

NCT06274047 · Androgen Axis Suppression, Prostatectomy, and more

RECRUITINGPhase 1/2

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

NCT07226986 · PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

RECRUITINGPhase 1/2

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more

RECRUITINGNA

Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

NCT07436078 · Female Breast Cancer, Prostate Cancer, and more

RECRUITINGNA

CARE Tool Study Aim 3

NCT07296887 · Gynecologic Cancer, Prostate Cancer, and more

View all related studies →

Continued Access of Focal MR-Guided Focused Ultrasound for Localized Intermediate Risk Prostate Lesions

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

CARE Tool Study Aim 3

Trial snapshot

Condition

Locations shown

For caregivers